PURPOSE: To develop a population physiologically-based pharmacokinetic (PBPK) model for simvastatin (SV) and its active metabolite, simvastatin acid (SVA), that allows extrapolation and prediction of their concentration profiles in liver (efficacy) and muscle (toxicity). METHODS: SV/SVA plasma concentrations (34 healthy volunteers) were simultaneously analysed with NONMEM 7.2. The implemented mechanistic model has a complex compartmental structure allowing inter-conversion between SV and SVA in different tissues. Prior information for model parameters was extracted from different sources to construct appropriate prior distributions that support parameter estimation. The model was employed to provide predictions regarding the effects of a range of clinically important conditions on the SV and SVA disposition. RESULTS: The developed model offered a very good description of the available plasma SV/SVA data. It was also able to describe previously observed effects of an OATP1B1 polymorphism (c.521 T > C) and a range of drug-drug interactions (CYP inhibition) on SV/SVA plasma concentrations. The predicted SV/SVA liver and muscle tissue concentrations were in agreement with the clinically observed efficacy and toxicity outcomes of the investigated conditions. CONCLUSIONS: A mechanistically sound SV/SVA population model with clinical applications (e.g., assessment of drug-drug interaction and myopathy risk) was developed, illustrating the advantages of an integrated population PBPK approach.
PURPOSE: To develop a population physiologically-based pharmacokinetic (PBPK) model for simvastatin (SV) and its active metabolite, simvastatin acid (SVA), that allows extrapolation and prediction of their concentration profiles in liver (efficacy) and muscle (toxicity). METHODS: SV/SVA plasma concentrations (34 healthy volunteers) were simultaneously analysed with NONMEM 7.2. The implemented mechanistic model has a complex compartmental structure allowing inter-conversion between SV and SVA in different tissues. Prior information for model parameters was extracted from different sources to construct appropriate prior distributions that support parameter estimation. The model was employed to provide predictions regarding the effects of a range of clinically important conditions on the SV and SVA disposition. RESULTS: The developed model offered a very good description of the available plasma SV/SVA data. It was also able to describe previously observed effects of an OATP1B1 polymorphism (c.521 T > C) and a range of drug-drug interactions (CYP inhibition) on SV/SVA plasma concentrations. The predicted SV/SVA liver and muscle tissue concentrations were in agreement with the clinically observed efficacy and toxicity outcomes of the investigated conditions. CONCLUSIONS: A mechanistically sound SV/SVA population model with clinical applications (e.g., assessment of drug-drug interaction and myopathy risk) was developed, illustrating the advantages of an integrated population PBPK approach.
Authors: Thomayant Prueksaritanont; Raju Subramanian; Xiaojun Fang; Bennett Ma; Yue Qiu; Jiunn H Lin; Paul G Pearson; Thomas A Baillie Journal: Drug Metab Dispos Date: 2002-05 Impact factor: 3.922
Authors: Michael J Knauer; Bradley L Urquhart; Henriette E Meyer zu Schwabedissen; Ute I Schwarz; Christopher J Lemke; Brenda F Leake; Richard B Kim; Rommel G Tirona Journal: Circ Res Date: 2009-11-25 Impact factor: 17.367
Authors: Marija Tubic-Grozdanis; John M Hilfinger; Gordon L Amidon; Jae Seung Kim; Paul Kijek; Petra Staubach; Peter Langguth Journal: Pharm Res Date: 2008-01-24 Impact factor: 4.200
Authors: Donglu Zhang; Cornelis E C A Hop; Gabriela Patilea-Vrana; Gautham Gampa; Herana Kamal Seneviratne; Jashvant D Unadkat; Jane R Kenny; Karthik Nagapudi; Li Di; Lian Zhou; Mark Zak; Matthew R Wright; Namandjé N Bumpus; Richard Zang; Xingrong Liu; Yurong Lai; S Cyrus Khojasteh Journal: Drug Metab Dispos Date: 2019-07-02 Impact factor: 3.922